|
KR20240093757A
(ko)
*
|
2014-06-02 |
2024-06-24 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
Cd19를 표적화하는 키메라 항원 수용체
|
|
WO2016149578A1
(en)
|
2015-03-19 |
2016-09-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Dual specific anti-cd22-anti-cd19 chimeric antigen receptors
|
|
JP6961490B2
(ja)
|
2015-04-08 |
2021-11-05 |
ノバルティス アーゲー |
Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
|
|
CN110650975B
(zh)
|
2017-05-15 |
2024-04-05 |
美国卫生和人力服务部 |
双顺反子嵌合抗原受体及其用途
|
|
IT201800003464A1
(it)
*
|
2018-03-13 |
2019-09-13 |
Ospedale Pediatrico Bambino Gesu |
Cellule T CAR-CD30 per il trattamento di tumori CD30+
|
|
EP3856782A1
(en)
*
|
2018-09-28 |
2021-08-04 |
Novartis AG |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
|
MX2021006968A
(es)
|
2018-12-12 |
2021-10-13 |
Kite Pharma Inc |
Antígeno quimérico y receptores de las células t, y métodos de uso.
|
|
WO2020146182A1
(en)
|
2019-01-08 |
2020-07-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross-species single domain antibodies targeting mesothelin for treating solid tumors
|
|
WO2020154150A1
(en)
|
2019-01-22 |
2020-07-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-1 and methods of use
|
|
KR20210129125A
(ko)
*
|
2019-02-20 |
2021-10-27 |
시티 오브 호프 |
Baff-r/cd19 표적화된 키메라 항원 수용체-변형된 t 세포 및 그의 용도
|
|
US20220160771A1
(en)
*
|
2019-04-10 |
2022-05-26 |
Iulia Diaconu |
Flt3-specific chimeric antigen receptors and methods of using the same
|
|
JP7711945B2
(ja)
|
2019-04-30 |
2025-07-23 |
センティ バイオサイエンシズ インコーポレイテッド |
キメラ受容体及びその使用方法
|
|
GB201906283D0
(en)
*
|
2019-05-03 |
2019-06-19 |
Moredun Res Institute |
Vector
|
|
AU2020268372A1
(en)
*
|
2019-05-07 |
2021-12-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Enhancement of polypeptides and chimeric antigen receptors via hinge domains
|
|
CA3139346A1
(en)
*
|
2019-05-07 |
2020-11-12 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Engineered immune cell targeting bcma and use thereof
|
|
US11162079B2
(en)
|
2019-05-10 |
2021-11-02 |
The Regents Of The University Of California |
Blood type O Rh-hypo-immunogenic pluripotent cells
|
|
JP7631234B2
(ja)
*
|
2019-05-31 |
2025-02-18 |
シティ・オブ・ホープ |
Ｃｄ３３陽性悪性腫瘍治療用ｃｄ３３標的化キメラ抗原受容体修飾ｔ細胞
|
|
EP3980453A4
(en)
*
|
2019-06-07 |
2023-07-05 |
The Trustees of the University of Pennsylvania |
Dual car expressing t cells individually linked to cd28 and 4-1bb
|
|
CN112390891B
(zh)
*
|
2019-08-14 |
2022-06-03 |
苏州方德门达新药开发有限公司 |
嵌合抗原受体及其构建方法和应用
|
|
AU2020371628A1
(en)
*
|
2019-10-21 |
2022-05-19 |
Purdue Research Foundation |
Engineered natural killer cells and methods for using the same in immunotherapy and autophagy inhibition techniques
|
|
CN119899265A
(zh)
|
2019-10-22 |
2025-04-29 |
美国政府(由卫生和人类服务部的部长所代表) |
用于治疗多种实体瘤的靶向b7h3（cd276）的高亲和力纳米抗体
|
|
US20220402998A1
(en)
*
|
2019-10-30 |
2022-12-22 |
The Texas A&M University System |
Protease switch for dual targets chimeric antigen receptor t cell therapy
|
|
BR112022009679A2
(pt)
*
|
2019-11-26 |
2022-08-09 |
Novartis Ag |
Receptores de antígeno quimérico cd19 e cd22 e usos dos mesmos
|
|
US20230092787A1
(en)
*
|
2020-02-17 |
2023-03-23 |
University Of Virginia Patent Foundation |
Car t cells targeting the integrin alphav beta3 exhibit robust anti-tumor responses against gliomas and other solid tumor malignancies
|
|
CN113493517B
(zh)
*
|
2020-04-02 |
2023-05-02 |
重庆精准生物技术有限公司 |
双特异性单链抗体及其构建的嵌合抗原受体和应用
|
|
CN113493516A
(zh)
*
|
2020-04-02 |
2021-10-12 |
重庆精准生物技术有限公司 |
靶向双特异性位点的嵌合抗原受体及其应用
|
|
CN111632135A
(zh)
*
|
2020-05-09 |
2020-09-08 |
深圳宾德生物技术有限公司 |
靶向nkg2d的嵌合抗原受体t细胞在治疗前列腺癌中的应用、治疗前列腺癌的药物
|
|
AU2021296423A1
(en)
*
|
2020-06-22 |
2023-02-02 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy
|
|
WO2022093745A1
(en)
|
2020-10-26 |
2022-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
TW202237827A
(zh)
|
2020-12-03 |
2022-10-01 |
美商世紀治療股份有限公司 |
經基因工程改造之細胞及其用途
|
|
WO2022133169A1
(en)
|
2020-12-18 |
2022-06-23 |
Century Therapeutics, Inc. |
Chimeric antigen receptor systems with adaptable receptor specificity
|
|
US11965022B2
(en)
|
2020-12-31 |
2024-04-23 |
Sana Biotechnology, Inc. |
Methods and compositions for modulating CAR-T activity
|
|
KR20230151513A
(ko)
|
2021-01-11 |
2023-11-01 |
사나 바이오테크놀로지, 인크. |
Cd8 표적 바이러스 벡터의 용도
|
|
CN112961245B
(zh)
*
|
2021-02-24 |
2023-07-25 |
重庆精准生物技术有限公司 |
一种靶向cd96的双特异性抗体及其制备方法和用途
|
|
WO2022232612A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
|
WO2022246293A1
(en)
|
2021-05-19 |
2022-11-24 |
Sana Biotechnology, Inc. |
Hypoimmunogenic rhd negative primary t cells
|
|
IL308097A
(en)
|
2021-05-27 |
2023-12-01 |
Sana Biotechnology Inc |
Hypoimmunogenic cells comprising engineered hla-e or hla-g
|
|
CA3216228A1
(en)
|
2021-06-09 |
2022-12-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting pd-l1 for treating solid tumors
|
|
AU2022309875A1
(en)
|
2021-07-14 |
2024-01-25 |
Sana Biotechnology, Inc. |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
|
WO2023015217A1
(en)
|
2021-08-04 |
2023-02-09 |
Sana Biotechnology, Inc. |
Use of cd4-targeted viral vectors
|
|
JP2024532772A
(ja)
|
2021-08-11 |
2024-09-10 |
サナ バイオテクノロジー，インコーポレイテッド |
低免疫原性細胞における遺伝子発現を変化させるための誘導性システム
|
|
MX2024001208A
(es)
|
2021-08-11 |
2024-04-22 |
Sana Biotechnology Inc |
Celulas primarias geneticamente modificadas para terapia celular alogenica.
|
|
JP2024534771A
(ja)
|
2021-08-11 |
2024-09-26 |
サナ バイオテクノロジー，インコーポレイテッド |
補体媒介性炎症反応を低減するための同種異系細胞療法のための遺伝子改変細胞
|
|
AU2022326565A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
|
WO2023019225A2
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
|
WO2023069790A1
(en)
|
2021-10-22 |
2023-04-27 |
Sana Biotechnology, Inc. |
Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
|
|
WO2023076881A1
(en)
|
2021-10-26 |
2023-05-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
|
|
EP4429767A1
(en)
|
2021-11-09 |
2024-09-18 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Igg4 hinge-containing chimeric antigen receptors targeting glypican-3 (gpc3) and use thereof
|
|
EP4448775A1
(en)
|
2021-12-17 |
2024-10-23 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
|
US20250059239A1
(en)
|
2021-12-17 |
2025-02-20 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
|
AU2022422147A1
(en)
|
2021-12-23 |
2024-07-04 |
Sana Biotechnology, Inc. |
Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
|
|
EP4463135A2
(en)
|
2022-01-10 |
2024-11-20 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
EP4472646A1
(en)
|
2022-02-01 |
2024-12-11 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
EP4473097A1
(en)
|
2022-02-02 |
2024-12-11 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
CN114478803B
(zh)
*
|
2022-02-11 |
2023-09-26 |
北京大学深圳研究生院 |
一种新型双特异性嵌合抗原受体的构建及其应用
|
|
US20250302953A1
(en)
|
2022-02-14 |
2025-10-02 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
|
AU2023221836A1
(en)
|
2022-02-15 |
2024-08-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cd28 hinge and transmembrane containing chimeric antigen receptors targeting gpc2 and use thereof
|
|
AU2023220128A1
(en)
|
2022-02-17 |
2024-08-22 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
EP4519294A1
(en)
*
|
2022-05-04 |
2025-03-12 |
Earli Inc. |
Methods using surface-expressable activatable epitopes to localize and/or treat diseased cells
|
|
WO2024040195A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
WO2024050399A1
(en)
|
2022-09-01 |
2024-03-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
|
|
EP4590688A1
(en)
|
2022-09-21 |
2025-07-30 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
WO2024097314A2
(en)
|
2022-11-02 |
2024-05-10 |
Sana Biotechnology, Inc. |
Methods and systems for determining donor cell features and formulating cell therapy products based on cell features
|
|
WO2024098038A2
(en)
|
2022-11-04 |
2024-05-10 |
Umoja Biopharma, Inc. |
Polynucleotide construct and related viral vectors and methods
|
|
EP4627096A1
(en)
|
2022-12-02 |
2025-10-08 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
|
WO2024220574A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
|
|
WO2024220597A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Digital droplet based assay for detecting replication competent lentiviral vector
|
|
WO2024220598A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Lentiviral vectors with two or more genomes
|
|
WO2024220560A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Engineered protein g fusogens and related lipid particles and methods thereof
|
|
WO2024238346A1
(en)
|
2023-05-12 |
2024-11-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies that specifically bind the s2 subunit of sars-cov-2 spike protein and compositions and uses thereof
|
|
AU2024274792A1
(en)
|
2023-05-23 |
2025-10-23 |
Sana Biotechnology, Inc. |
Tandem fusogens and related lipid particles
|
|
WO2024249954A1
(en)
|
2023-05-31 |
2024-12-05 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2025006799A1
(en)
|
2023-06-27 |
2025-01-02 |
Capstan Therapeutics, Inc. |
Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
|
|
WO2025019228A1
(en)
|
2023-07-20 |
2025-01-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
|
|
WO2025043172A1
(en)
|
2023-08-23 |
2025-02-27 |
Sana Biotechnology, Inc. |
Modified cd47 proteins and their uses
|
|
WO2025054202A1
(en)
|
2023-09-05 |
2025-03-13 |
Sana Biotechnology, Inc. |
Method of screening a sample comprising a transgene with a unique barcode
|
|
WO2025054290A1
(en)
*
|
2023-09-06 |
2025-03-13 |
Baylor College Of Medicine |
Cd19 chimeric antigen receptors
|
|
WO2025076048A1
(en)
*
|
2023-10-02 |
2025-04-10 |
Fred Hutchinson Cancer Center |
Anti-cd90 antibodies, binding fragments, and uses thereof
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
US20250127728A1
(en)
|
2023-10-05 |
2025-04-24 |
Capstan Therapeutics, Inc. |
Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
|
|
WO2025096878A1
(en)
|
2023-11-02 |
2025-05-08 |
Capstan Therapeutics, Inc. |
Rna for in vivo transfection with increased expression
|
|
US20250332281A2
(en)
|
2023-12-15 |
2025-10-30 |
Capstan Therapeutics, Inc. |
Humanized anti-cd8 antibodies and uses thereof
|
|
WO2025151838A1
(en)
|
2024-01-12 |
2025-07-17 |
Sana Biotechnology, Inc. |
Safety switches to control in vitro and in vivo proliferation of cell therapy products
|
|
WO2025158420A1
(en)
|
2024-01-25 |
2025-07-31 |
Nanocell Therapeutics Holdings B.V. |
Methods and composition for inducing activation and dna expression in t-cells
|
|
WO2025171238A1
(en)
|
2024-02-07 |
2025-08-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof
|
|
WO2025169168A1
(en)
|
2024-02-09 |
2025-08-14 |
Nanocell Therapeutics Holdings B.V. |
Extracorporeal transfection of immune effector cells
|
|
US20250302763A1
(en)
|
2024-02-22 |
2025-10-02 |
Capstan Therapeutics, Inc. |
Immune engineering amplification
|
|
WO2025184529A1
(en)
|
2024-03-01 |
2025-09-04 |
Sana Biotechnology, Inc. |
Viral particles with fusogen display and related compositions and methods
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|
|
WO2025235598A1
(en)
|
2024-05-09 |
2025-11-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting glypican-2 and/or cd276 and their use for treating solid tumors
|